Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia

  • Authors:
    • Kyeong Seok Kim
    • Hun Yong Yang
    • Seung‑Cheol Chang
    • Young‑Mi Kim
    • Kwang Youl Lee
    • Byung Mu Lee
    • Hyung Sik Kim
  • View Affiliations

  • Published online on: July 5, 2018     https://doi.org/10.3892/ijmm.2018.3759
  • Pages:2260-2268
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Benign prostatic hyperplasia (BPH) is one of the leading causes of male reproductive disorders. Therapeutic agents currently in use have severe side effects; therefore, alternative drugs that exhibit improved therapeutic activity without side effects are required. The present study investigated the protective effect of GV1001 against testosterone‑induced BPH in rats. BPH in castrated rats was established via daily subcutaneous (s.c.) injections of testosterone propionate (TP, 3 mg/kg) dissolved in corn oil for 4 weeks. GV1001 (0.01, 0.1 and 1 mg/kg, s.c.) was administered 3 times per week for 4 weeks, together with TP (3 mg/kg) injection. The rats were sacrificed on the last day of treatment, and their prostates were excised and weighed for biochemical and histological studies. Serum levels of testosterone and dihydrotestosterone (DHT) were also measured. In rats with TP‑induced BPH, a significant increase in prostate weight (PW) and prostatic index (PI), accompanied by a decrease in antioxidant enzyme activity, was observed. Histological studies revealed clearly enlarged glandular cavities in rats with BPH. GV1001 (0.01 and 0.1 mg/kg) treatment significantly decreased PW and PI in rats with TP‑induced BPH. In addition, GV1001 demonstrated a potent inhibitory effect on 5α‑reductase in prostate. The present data suggest that the protective role of GV1001 against testosterone‑induced BPH is closely associated with its antioxidant potential. Additional studies are required to identify the mechanisms by which GV1001 protects against BPH to determine its clinical application.

Related Articles

Journal Cover

October 2018
Volume 42 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kim, K.S., Yang, H.Y., Chang, S., Kim, Y., Lee, K.Y., Lee, B.M., & Kim, H.S. (2018). Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia. International Journal of Molecular Medicine, 42, 2260-2268. https://doi.org/10.3892/ijmm.2018.3759
MLA
Kim, K. S., Yang, H. Y., Chang, S., Kim, Y., Lee, K. Y., Lee, B. M., Kim, H. S."Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia". International Journal of Molecular Medicine 42.4 (2018): 2260-2268.
Chicago
Kim, K. S., Yang, H. Y., Chang, S., Kim, Y., Lee, K. Y., Lee, B. M., Kim, H. S."Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia". International Journal of Molecular Medicine 42, no. 4 (2018): 2260-2268. https://doi.org/10.3892/ijmm.2018.3759